Acute otitis media (AOM) is a leading cause of visits to physicians and of antibiotic prescriptions for young children. We systematically reviewed studies on all-cause AOM episodes and physician visits in which impact was attributed to pneumococcal conjugate vaccines, either as efficacy or effectiveness. Of 18 relevant publications found, most used the 7-valent pneumococcal conjugate vaccine (7vCRM). The efficacy of 7vCRM against all-cause AOM episodes or visits was 0-9 in randomized trials and 17-23 in nonrandomized trials. In observational database studies, physician visits for AOM were already declining in the 3-5 years before 7vCRM introduction (mean change,-15; range, +14 to-24) and continued to decline afterward (mean,-19; range, +7 to-48). This vaccine provides some protection against OM, but other factors have also contributed to the recent decline in OM incidence. Future effectiveness studies should thus use better-controlled methods to estimate the true impact of vaccination on AOM.
Impact of pneumococcal conjugate vaccination on otitis media: a systematic review / S. Taylor, P. Marchisio, A. Vergison, J. Harriague, W. P. Hausdorff, M. Haggard. - In: CLINICAL INFECTIOUS DISEASES. - ISSN 1058-4838. - 54:12(2012 Jun), pp. 1765-1773.
Impact of pneumococcal conjugate vaccination on otitis media: a systematic review
P. Marchisio
;
2012
Abstract
Acute otitis media (AOM) is a leading cause of visits to physicians and of antibiotic prescriptions for young children. We systematically reviewed studies on all-cause AOM episodes and physician visits in which impact was attributed to pneumococcal conjugate vaccines, either as efficacy or effectiveness. Of 18 relevant publications found, most used the 7-valent pneumococcal conjugate vaccine (7vCRM). The efficacy of 7vCRM against all-cause AOM episodes or visits was 0-9 in randomized trials and 17-23 in nonrandomized trials. In observational database studies, physician visits for AOM were already declining in the 3-5 years before 7vCRM introduction (mean change,-15; range, +14 to-24) and continued to decline afterward (mean,-19; range, +7 to-48). This vaccine provides some protection against OM, but other factors have also contributed to the recent decline in OM incidence. Future effectiveness studies should thus use better-controlled methods to estimate the true impact of vaccination on AOM.File | Dimensione | Formato | |
---|---|---|---|
Clin Infect Dis.-2012-Taylor-1765-73.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
209.78 kB
Formato
Adobe PDF
|
209.78 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.